Back to search
FDAFDA · Food and drugs·Recall number Z-2618-2014

The BD MAX MRSA Assay, catalogue #442953. An automated qualitative in vitro diagnostic test for the direct detection of Methicillin-resistant Staphylococcus aureus (MRSA) DNA from nasal swabs in patie.

Published September 17, 2014 · Recall initiated: July 23, 2014

Summary

FDA records medical device Class II recall Z-2618-2014, published September 17, 2014 and initiated July 23, 2014. Recalling firm: Becton Dickinson & Co.; Status: Terminated; Reported quantity: 585,048 tests; Lot: All Lots with the expiration date January 21, 2014 or later. Class II means possible temporary or medically reversible effects, or a remote probability of serious health consequences.

Status when published: Terminated — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.

What's the hazard

The performance of the assay no longer conforms to this statement in the Analytical Specificity section of the Package Insert: One hundred-eleven (111) out of 111 MSSA strains tested at extremely high concentrations (> 106 CFU/swab), produced negative results with the BD MAX MRSA Assay. One of the samples tested with each of the CAP surveys MRS5-A 2014 and MRS5-B 2014 yielded false positive results.

What to do

Voluntary: Firm initiated · Letter

Get an email when a new FDA recall like this is published

Free. We only write when there's a new recall that matches. Unsubscribe in one click.

Recall details

Manufacturer
Becton Dickinson & Co.
Distributor
US Distribution including the states of : CA, FL, HI, IL, IN, MD, MI, MN, MT, NC, ND, NJ, NM, NV, NY, OH, OK, OR, PA, SC, TN, TX, UT, VA, WA and WI.
Lot
All Lots with the expiration date January 21, 2014 or later
Risk classification
Class II
Area (FDA)
device
Country
United States

Related recalls

Questions about this recall

Was The BD MAX MRSA Assay, catalogue #442953. An automated qualitative in vitro diagnostic test for the direct detection of Methicillin-resistant Staphylococcus aureus (MRSA) DNA from nasal swabs in patie. recalled?

Yes. FDA published recall Z-2618-2014 on September 17, 2014. Reported hazard: The performance of the assay no longer conforms to this statement in the Analytical Specificity section of the Package Insert: One hundred-eleven (111) out of 111 MSSA strains tested at extremely high concentrations (> 106 CFU/swab), produced negative results with the BD MAX MRSA Assay. One of the samples tested with each of the CAP surveys MRS5-A 2014 and MRS5-B 2014 yielded false positive results.

What should I do if I have this product?

Voluntary: Firm initiated · Letter